AT 65474
Alternative Names: AT-65474Latest Information Update: 26 Jul 2024
At a glance
- Originator Axcynsis Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 05 Apr 2024 Preclinical trials in Solid tumours in Singapore (Parenteral), prior to April 2024
- 05 Apr 2024 Pharmacodynamics and adverse event data from preclinical trials in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Axcynsis Therapeutics plans a phase I trial for Solid tumours in 2024 (Axcynsis Therapeutics pipeline, April 2024)